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Abstract: Leber hereditary optic neuropathy (LHON) is an important 
cause of mitochondrial blindness. The majority of patients harbor one 
of three mitochondrial DNA (mtDNA) point mutations, m.3460G>A, 
m.11778G>A, and m.14484T>C, which all affect complex I subunits of 
the mitochondrial respiratory chain. The loss of retinal ganglion cells in 
LHON is thought to arise from a combination of impaired mitochondrial 
oxidative phosphorylation resulting in decreased adenosine triphosphate 
(ATP) production and increased levels of reactive oxygen species. Treat-
ment options for LHON remain limited, but major advances in mitochon-
drial neuroprotection, gene therapy, and the prevention of transmission 
of pathogenic mtDNA mutations will hopefully translate into tangible 
benefits for patients affected by this condition and their families.
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Leber hereditary optic neuropathy (LHON) typically presents with acute or subacute painless central visual loss in young 
adults with a peak age of onset in the third decade of life.1 It is a 
bilateral disease and the majority of patients present with visual 
loss in one eye followed by the fellow eye usually 3–6 months 
later.2 In about 25% of cases, both eyes are affected simultane-
ously.3 The prevalence of LHON has been estimated to be about 1 
in 30,000 and it is the most common primary mitochondrial DNA 
(mtDNA) disease in the population.4 About 90% of LHON car-
riers harbor one of three mtDNA point mutations (m.3460G>A, 
m.11778G>A, and m.14484T>C), with the m.11778G>A 
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mutation being the most common cause of LHON worldwide ac-
counting for 70–90% of all cases.5–7 Leber hereditary optic neu-
ropathy is characterized by marked incomplete penetrance and a 
male sex bias. Although a wide variability is observed between 
families, on average, the lifetime risk of visual loss for a male 
LHON carrier is about 50% compared with 10% for a female 
LHON carrier. Leber hereditary optic neuropathy results in se-
vere central visual loss and the visual prognosis is poor with most 
patients remaining registered legally blind for the rest of their 
lives.8 There are currently limited treated options for LHON, but 
a better understanding of the disease mechanisms that underpin 
retinal ganglion cell (RGC) loss in this disorder and transforma-
tive technological advances are opening new exciting avenues for 
therapeutic intervention.
MITOCHONDRIAL NEUROPROTECTION
Mitochondria produce adenosine triphosphate (ATP) through 
a complex series of biochemical reactions that involve the trans-
fer of high-energy electrons along the mitochondrial respiratory 
chain. Reactive oxygen species (ROS) are an inevitable byprod-
uct of mitochondrial oxidative phosphorylation and the levels 
are tightly regulated in physiological states to minimize oxida-
tive damage to mitochondrial membranes and mtDNA. Unsur-
prisingly, mitochondrial dysfunction is associated with impaired 
ATP synthesis and increased ROS production, both of which 
contribute to the neurodegenerative consequences of pathogenic 
mtDNA mutations. A variety of mitochondrial cocktails consist-
ing of supplements such as carnitine, creatine and L-arginine, and 
multivitamins have been used to counteract these deleterious con-
sequences, but the evidence base for efficacy is weak.3,9 
Ubiquinone is an essential carrier within the inner mito-
chondrial membrane that ensures the efficient transfer of elec-
trons along the mitochondrial respiratory chain from complexes 
I and II to complex III.10 Co-enzyme Q10 (CoQ10) and ideben-
one are two well-known ubiquinone analogs that are frequent-
ly prescribed to patients with mitochondrial disease. These two 
molecules have different molecular sizes and pharmacokinetics, 
and CoQ10, unlike idebenone, is not able to cross the blood-brain 
barrier.11 Idebenone was therefore an obvious drug candidate for 
LHON and its safety and efficacy was investigated as part of a 
randomized controlled trial (RHODOS) that recruited 85 pa-
tients carrying the m.3460G>A, m.11778G>A, and m.14484T>C 
mtDNA mutations.12 The patients were randomized in a 2:1 ra-
tio to idebenone (300 mg three times per day) or placebo for a 
period of 24 weeks. Although RHODOS failed its primary out-
come measure, a subgroup of treated patients was found to ben-
efit and this observation was confirmed in a larger retrospective 
case series of 103 patients treated with variable doses of ideben-
one.13 Based on the cumulative body of evidence, idebenone was 
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approved by the European Medicine Agency under exceptional 
circumstances in June 2015 for use in patients with visual loss 
from LHON.14 A recently convened expert panel has recommend-
ed that idebenone should be started as soon as possible (at a dose 
of 300 mg three times per day) for patients with LHON with vi-
sual loss of less than one year. This regimen should be continued 
for at least one year to determine whether there is a treatment 
effect and if a clinically relevant response is observed, treatment 
should be continued for one year after the plateau phase has been 
reached.15 The expert panel concluded that there was not enough 
evidence to recommend treatment for chronic LHON cases. 
Given that impaired mitochondrial bioenergetics and oxidative 
damage are major pathophysiological players in LHON, other 
molecules with neuroprotective properties are being considered, 
including EPI-743 and MTP-131.16,17 These two drug compounds 
and other future ones will need to be rigorously assessed as part 
of properly powered trials with a sufficiently long period of treat-
ment to determine whether they can improve the visual prognosis 
in LHON.18
MITOCHONDRIAL BIOGENESIS
Compared with the nuclear genome, mitochondria have a 
very high copy number genome, which can lead to an admixture 
of different mtDNA variants. Mitochondrial biogenesis refers to 
the tightly regulated process that controls the cell’s mtDNA copy 
number under both physiological and pathological states, which 
can also be influenced by environmental factors. Leber hereditary 
optic neuropathy is emerging as a complex multifactorial disease 
and there is now convincing evidence linking environmental 
triggers, in particular smoking, with an increased risk of visual 
loss among at-risk carriers.19 However, the prominent male bias 
seen in this mitochondrial disorder requires further explanations 
and hormonal factors have emerged as possible disease modifi-
ers given the obvious differences between the sexes.20 Estrogen 
derivatives have been found to reduce ROS levels and rescue 
the viability of LHON cell lines, and this improved survival has 
been ascribed to an upregulation of mitochondrial biogenesis.21,22 
This encouraging in vitro data is supported by the observation 
made in human blood samples with unaffected LHON carriers 
having a higher mtDNA copy number compared with those who 
have experienced visual loss from LHON, pointing towards a 
neuroprotective effect.22 Furthermore, patient cell lines exposed 
to cigarette extracts show a decrease in mtDNA copy number, 
impaired mitochondrial oxidative phosphorylation, and ROS de-
toxification, providing a strong causal link between smoking and 
an increased risk of visual loss in LHON.23
GENE THERAPY
The eye is ideally suited for gene therapy and the develop-
ment of safe and effective viral delivery vector systems have led 
to several development programs for inherited eye diseases.24,25 
Gene therapy for LHON has been hampered by the double mem-
brane structure of mitochondria and the relatively impervious 
properties of the mitochondrial inner membrane.26 To circumvent 
these physical barriers, an indirect approach, known as allotopic 
expression, has been developed whereby the replacement gene 
of interest is delivered to the nuclear genome with a modified 
adeno-associated virus (AAV) vector and the encoded protein has 
a mitochondrial targeting sequence, which allows for its import 
into the mitochondrial compartment.27,28 Preclinical studies for the 
MT-ND4 mutation (m.11778G>A) have shown rescue of the cel-
lular phenotype and RGCs in murine models of LHON.29,30 Based 
on these findings, a number of clinical trials have been initiated 
using AAV2 viral delivery systems and the preliminary results 
are encouraging, suggesting that allotopic expression could be 
an effective strategy to preserve RGCs and improve visual func-
tion.31–34 It should be stressed that the visual benefit of this gene 
therapy approach for LHON still requires confirmation, including 
the best window of opportunity for intervention and whether the 
effect can be sustained after a single intravitreal injection of the 
viral vector. There are also some concerns about the level of RGC 
transfection with this mode of delivery and whether the imported 
ND4 subunit will integrate and form a stable complex I structure, 
which require further investigation.35
MITOCHONDRIAL REPLACEMENT THERAPY
As the mitochondrial genome shows strict maternal inheri-
tance, preventing the transmission of pathogenic mtDNA muta-
tions from mother to child has gained considerable attention over 
the past few years.36 Mitochondrial replacement therapy (or mito-
chondrial donation) is a modified in vitro fertilization technique 
that involves the transfer of the parental nuclear material into a 
mitochondrial donor zygote carrying only wild-type mtDNA.37,38 
If the resulting embryo proceeds to a full-term pregnancy, the 
child’s mitochondrial genome will be from the maternal donor 
and there have been some concerns about possible mismatch 
with the nuclear genome inherited from the biological parents.39,40 
Furthermore, as mitochondrial donation involves germline mod-
ification and any detrimental consequences might not become 
apparent until several years after birth, there is an ongoing eth-
ical debate about the clinical application of this technique, more 
so for mitochondrial disorders such as LHON that are not life 
threatening.41,42 The course of the argument was somewhat over-
taken when it became public knowledge in September 2016 that a 
healthy child had been born in Mexico from mitochondrial dona-
tion.43,44 The child’s mother is heteroplasmic for the m.8993T>G 
mtDNA mutation in MT-ATP6, which in addition to the syndrome 
of neuropathy, ataxia, and retinitis pigmentosa (NARP) can also 
cause Leigh syndrome when present at high mutant levels. Al-
though clinically asymptomatic, she suffered from multiple mis-
carriages and two of her children died at the age of 8 months and 
6 years old from Leigh syndrome with the m.8993T>G mutation 
detected at levels exceeding 95%. The mutation was present a low 
level of heteroplasmy (2.4–9.2%) in the tissues obtained from 
the child and his development will be closely monitored until he 
reaches the age of 18 years old. A population-based study in the 
United Kingdom has estimated that about 150 female carriers of 
childbearing age would benefit from mitochondrial replacement 
therapy per year, with a significant proportion being mtDNA 
LHON carriers.45 The law was modified in 2015 in the United 
Kingdom to allow for this technique to be used in strictly regulat-
ed clinics and as part of a long-term child follow-up program.45 
After a period of consultation, the Food and Drug Administration 
has concluded that further experimental and safety data are need-
ed before mitochondrial replacement therapy can be considered 
as a reproductive option for women carrying disease-causing 
mtDNA mutations.46
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LOOKING INTO THE FUTURE
A landmark discovery was the observation that somatic cells, 
such as fibroblasts, could be transformed into induced pluripo-
tent stem cells (iPSCs) with a combination of virally delivered 
reprogramming factors.47 Research into LHON and other mito-
chondrial optic neuropathies has been severely limited by our 
inability to study disease mechanisms and treatment paradigms 
directly in RGCs. The advent of this powerful and versatile tech-
nology has the potential to be transformative and a number of 
research groups have generated LHON iPSC lines to address 
these fundamental gaps in our knowledge base.48,49 The differ-
entiation of iPSCs into RGCs needs to be optimized further to 
generate a sufficient amount of cells for experimental manipu-
lation and high-throughput drug screening, which will require 
close collaboration with industrial partners.50 Although RGC re-
placement remains a challenging endeavor given the need for the 
transplanted cells to make the right retinotopic connections, it is 
possible that they could exert a neuroprotective influence, more 
so if genetically modified to overexpress RGC trophic factors 
that block the deleterious consequences of an underlying mtDNA 
mutation.51
CONCLUSIONS
Leber hereditary optic neuropathy is a devastating disease 
with major long-term consequences for patients and their fami-
lies. Until recently, the management of this condition was limited 
to visual rehabilitation, genetic counseling, and the avoidance of 
potential environmental triggers. Research into LHON has now 
reached an important translational phase and there is consider-
able hope that a combination of approaches ranging from RGC 
neuroprotection to gene therapy and mitochondrial replacement 
therapy will help improve the visual prognosis for patients or 
achieve the breakthrough of preventing the maternal transmission 
of the causative mtDNA mutation. Although the road ahead re-
mains challenging with the need for multidisciplinary collabo-
rations and substantial research funding for clinical trials, there 
is certainly light at the end of the tunnel in our efforts to develop 
effective treatments for LHON.
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